Q3 2025
Released Nov 6, 2025, after the close
10-Q filed Nov 6, 2025, 37 days after period end · 0001493152-25-021061
Q3 2025 · 10-Q
Revenue$4.76M$4.76M +35.4% vs Q3 2024+7.8% vs Q2 2025
Net Income$337.00K$337.00K +84.2% vs Q3 2024+42.2% vs Q2 2025
EPS Diluted$0.03$0.03 +50.0% vs Q3 2024+50.0% vs Q2 2025
Gross Profit$2,915,000+35.6%
Operating Income$314,000+52.4%
Operating Cash Flowderived$99,000N/M
Margins · derived
Gross margin61.2%+0.1 pt vs Q3 2024
Operating margin6.6%+0.7 pt vs Q3 2024
Net margin7.1%+1.9 pt vs Q3 2024
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $4.76M | $3.52M | $3.74M | $2.41M |
| Net Income | $337.00K | $183.00K | -$182.00K | -$3.23M |
| EPS Diluted | $0.03 | $0.02 | -$0.02 | -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR